Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of guadecitabine vs treatment choice in previously treated AML
jRCT2080223674Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of guadecitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Oct 2017; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223674.